A recent meta-analysis also suggested that NAT is associated with a lower risk of development of lymph node metastasis, an improved R0 resection rate, and improved recurrence-free and overall survivals in patients with resectable disease [11]. Here, BRD2 is linked to metastatic malignant neoplasm in the lymph nodes.